Myeloid cell lines: Tools for studying differentiation of normal and abnormal hematopoietic cells

doi:10.1016/0268-960X(88)90034-3

Blood Reviews

Volume 2, Issue 2, June 1988, Pages 121-133

https://doi.org/10.1016/0268-960X(88)90034-3 Get rights and content

Abstract

Acute myeloid leukemia is caused by one or several transforming events which usually result in a block of myeloid precursor cell maturation. Human cell lines can serve as model for hematopoietic cells arrested at different stages of myeloid differentiation. These homogeneous populations help to dissect the cellular and molecular events involved in leukemogenesis, such as proto-oncogene activation. Furthermore, the efficacy and mechanism of action of compounds inducing differentiation of leukemic cells can be studied. Finally, these lines can permit the analysis of proliferation and differentiation of normal myeloid precursor cells.

References (147)

H.P. Koeffler
Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications
Blood
(1983)
C.B. Lozzio et al.
Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome
Blood
(1975)
H.P. Koeffler et al.
An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1)
Blood
(1980)
R.C. Stong et al.
Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics
Blood
(1985)
H.P. Koeffler et al.
Human myeloid leukemia cell lines: A review
Blood
(1980)
T Ohkubo et al.
A novel Ph1 chromosome positive cell line established from a patient with chronic myelogenous leukemia in blastic crisis
Leukemia Research
(1985)
A.J. Treves et al.
In vitro differentiation and establishment of cell lines derived from human myelomonocytic leukemia cells
Immunology Letters
(1986)
B.S. Andersson et al.
Ph¹-positive chronic myeloid leukemia with near-haploid conversion in vivo and establishment of a continuously growing cell line with similar cytogenetic pattern
Cancer Genetics and Cytogenetics
(1987)
A.K. Sullivan et al.
Deficiency of myeloperoxidase and abnormal chromosome 1 occurs in variant (HL60) promyelocytes
Leukemia Research
(1986)
I Kubonishi et al.
Establishment of a new peroxidase-positive human myeloid cell line, PL-21
Blood
(1984)

H Ben Bassat et al.

Establishment and characterization of a new permanent cell line (GDM-1) from a patient with acute myelomonocytic leukemia

Leukemia Research

(1982)

T Mori et al.

Ph1-positive CML-derived myeoloid-monocytoid precursor cell line producing substance(s) that stimulates normal CFU-C

Leukemia Research

(1987)

K.A. Tucker et al.

Characterization of a new human diploid myeoloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity

Blood

(1987)

K Kishi

A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors

Leukemia Research

(1985)

H Saito et al.

Establishment and characterisation of a new human eosinophilic leukemia cell line

Blood

(1985)

M Ogura et al.

Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome

Blood

(1985)

A Palumbo et al.

Lineage infidelity of a human myelogenous leukemia cell line

Blood

(1984)

A.J. Furley et al.

Divergent molecular phenotypes of KG1 and KG1a myeloid cell lines

Blood

(1986)

J.H. Pierce et al.

Neoplastic transformation of mast cells by Abelson-MuLV: Abrogation of IL-3 dependence by a nonautocrine mechanism

Cell

(1985)

J Minowada et al.

A non-T, non-B human leukemia cell line (NALM-1): Establishment of the cell line and presence of leukemia-associated antigens

Journal of the National Cancer Institute

(1977)

J.L. Bos et al.

Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia

Nature

(1985)

H Hirai et al.

A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome

Nature

(1987)

N.C. Reich et al.

Growth regulation of a cellular tumour antigen, p53, in nontransformed cells

Nature

(1984)

H Tanaka et al.

1α25 dihydroxycholecalciferol and a human myeloid leukemic cell line (HL-60)

Biochemistry Journal

(1982)

K Takeda et al.

Identity of differentiation inducing factor and tumour necrosis factor

Nature

(1986)

CG Begley et al.

Purified colony stimulating factors (G-CSF and GM-CSF) induce differentiation in human HL-60 leukemic cells with suppression of clonogenicity

International Journal of Cancer

(1987)

HP Koeffler et al.

γ-Interferon induces expression of the HLA-D antigens on normal and leukemic human myeloid cells

TJ Chaplinski et al.

Cyclic nucleotide-induced maturation of human promyelocytic leukemia cells

Journal of Clinical Investigation

(1982)

L Sachs

Constitutive uncoupling of pathways of gene expression that control growth and differentiation in myeloid leukemia. A model for the origin and progression of malignancy

S.J. Collins et al.

Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture

Nature

(1977)

H.P. Koeffler et al.

Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity

Science

(1978)

L Pegoraro et al.

Establishment of a Ph¹-positive human cell line (BV173)

Journal of the National Cancer Institute

(1983)

I Kubonishi et al.

Establishment of a Ph¹-chromosome positive cell line from chronic myelogenous leukemia in blast crisis

International Journal of Cell Cloning

(1983)

I Kubonishi et al.

Two new human myeloid cell lines derived from acute promyelocytic leukemia and chronic myelocytic leukemia

Gann

(1983)

A Keating et al.

EM-2 and EM-3: two new Ph¹+ myeloid cell lines

D.L. Lucas et al.

Isolation of a new human myeloid leukeumia cell line, RDFD-2, and the preparation of clonal derivative lines with differing capacities to undergo induced maturation

Blood

(1983)

P Martin

HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression

Science

(1982)

K Takeda et al.

Kinetics of appearance of differentiation associated characteristics in ML-1, a line of human mycloblastic leukemia cells, after treatment with 12-0-tetradecanoylphorbol 13-acetate, dimethyl sulfoxide, 1-beta-D-arabinofuranoslycytosine

Cancer Research

(1982)

T.R. Bradley et al.

Cell lines derived from a human monomyelocytic leukemia

British Journal of Haematology

(1982)

S.Z. Salahuddin et al.

Establishment, characterization and differentiation induction of a new human diploid myelomonocytic cell line (HL92) derived from a patient with acute myelomonocytic leukemia

Leukemia Research

(1982)

H.G. Drexler et al.

Monocytoid leukemia cell line CTV-I: morphological, immunological and isoenzymatic characteristics

Tumour Biology

(1986)

A.J. Treves et al.

A new myeolomonoblastic cell line (M20): analysis of properties, differentiation, and comparison with other established lines of similar origin

Experimental Hematology

(1985)

H Ohno et al.

Establishment of a new myeloid leukemia cell line (TK-1), and isolation of a new myeloid leukemia cell line (TK-1), and isolation of cells having a translocation involving band 17q23

International Journal of Cancer

(1986)

C Sundström et al.

Establishment and characterization of a human histiocytic lymphoma cell line (U-937)

International Journal of Cancer

(1976)

S Tsuchiya et al.

Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)

International Journal of Cancer

(1980)

M Ohta et al.

Establishment and characterization of four human monocytoid leukemia cell lines (JOSK-I, -S, -M and -K) with capabilities of monocyte-macrophage lineage differentiation and constitutive production of interleukin I

Cancer Research

(1986)

G Monaco et al.

Induction of monocyte/macrophage differentiation in a new diploid line of human hematopoetic cells (CM-S) by phorbol esters

Cancer Research

(1982)

Y Nagata et al.

The generation of human monoctye/macrophage cell lines

Nature

(1983)

T Tange et al.

Induction of megakaryocytic maturation of a human megakaryoblastic cell line

Experimental Hematology

(1987)

T Sato et al.

Establishment and characterization of a megakaryoblastic cell line (CMK) from a Down's syndrome patient with acute megakaryoblastic leukemia

Experimental Hematology

(1987)

Cited by (46)

Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression
2019, Experimental Hematology
Citation Excerpt :
Cell lines derived from AML patient cells are extensively used to identify therapeutic agents in vitro and in vivo. However, the majority of leukemia cell lines have complex cytogenetics and many of the existing lines are not representative of a recurring subset of AML patients [36]. In this report, we describe OCI-AML-20, a new EVI1-rearranged cell line that complements the previously described cell lines with inv(3) UCSD-AML1 and MUTZ-3 [7,8].
Acute myeloid leukemia (AML) is a complex, heterogeneous disease with variable outcomes following curative intent chemotherapy. AML with inv(3) is a genetic subgroup characterized by a very low response rate to current induction type chemotherapy and thus has among the worst long-term survivorship of the AMLs. Here, we describe OCI-AML-20, a new AML cell line with inv(3) and deletion of chromosome 7; the latter is a common co-occurrence in inv(3) AML. In OCI-AML-20, CD34 expression is maintained and required for repopulation in vitro and in vivo. CD34 expression in OCI-AML-20 shows dependence on the co-culture with stromal cells. Transcriptome analysis indicates that the OCI-AML-20 clusters with other AML patient data sets that have poor prognosis, as well as other AML cell lines, including another inv(3) line, MUTZ-3. OCI-AML-20 is a new cell line resource for studying the biology of inv(3) AML that can be used to identify potential therapies for this poor outcome disease.
Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH)
2009, Leukemia Research
Citation Excerpt :
Most of the described human myeloid leukemia cell lines are derived from aggressive or relapsed cases and have multiple cytogenetic aberrations. There are few reviews regarding myeloid leukemia cell lines [1,2]. We have established and describe here a new myeloid leukemia cell line with normal cytogenetics.
A new myeloid leukemia cell line (CG-SH) with normal cytogenetics was established from a patient with acute myelogenous leukemia (AML) following myelodysplastic syndrome (MDS). The cells of CG-SH are immature blasts and have an immature myeloid phenotype (positive for myeloperoxidase, CD7, CD34, CD38, CD117, HLA-DR, negative for CD10, CD19, CD20, CD41, CD42). A partial expression of CD13, CD15, CD65 and a weak expression of CD33 and CD133 was noted. The cells are negative for EBER. By molecular analysis, a mutation of NRAS and heterozygous mutations of RUNX1 were detected. No mutations were detected in FLT3-ITD, MLL-PTD or NPM1. By real-time PCR, a series of 19 microRNAs was identified which are strongly expressed in CG-SH. In conclusion, a new cell line was established which will be useful for the study of AML with normal cytogenetics and mutations in NRAS and/or RUNX1.
Myeloid leukemia cell growth and differentiation are independent of mitogen-activated protein kinase ERK1/2 activation
2000, Journal of Biological Chemistry
Citation Excerpt :
pCDNAHA-ERK2 and -ERK1 were transfected by electroporation, after which cells were incubated for 48 h and serum-starved, and kinase assays were performed as described above using anti-HA antibody for immunoprecipitation. In this study, we have chosen a series of cell lines representative of the two main types of myeloid leukemias, including K562, KBM5, and KU812, typical Philadelphia-positive, chronic myelogenous leukemia lines, and HL60 and U937 archetypes of acute myeloid leukemias (9). We also included murine 32D cells that are diploid, nontumorogenic, interleukin-3-dependent myeloid progenitor cells (37, 38).
The mitogen-activated protein kinase ERK1/2 pathway is essential in the control of cell proliferation and differentiation in most cellular systems. As such, it has been considered a potential target for antineoplastic therapy. For this purpose, we have examined the role of ERK activation in myeloid leukemia cell growth and differentiation. Using a representative set of myeloid leukemia cell lines, we show that cell proliferation was not accompanied by increases on ERK1/2 activation, and mitogenic stimulation did not enhance ERK activity. Moreover, abolition of ERK function by the inhibitor PD98059 or by a dominant inhibitory mutant ERK2 had no significant effects on proliferation. With the aid of various differentiation inducers, we found that within the same cell line, differentiation to a given lineage could occur with and without ERK1/2 activation, depending on the stimulus. Also, a differentiator could have the same effect in the presence or absence of ERK stimulation, depending on the cell line. ERK inhibition did not affect the differentiation elicited by stimuli whose effects were accompanied by ERK activation. Finally, constitutive ERK activity was also ineffective on proliferation and differentiation. Thus, our results indicate that ERK1/2 activation is not an essential requirement for leukemic cell growth and differentiation.
Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research
2000, Leukemia Research
Along with other improvements, the advent of continuous human leukemia–lymphoma (LL) cell lines as a rich resource of abundant, accessible and manipulable living cells has contributed significantly to a better understanding of the pathophysiology of hematopoietic tumors. The first LL cell lines, Burkitt's lymphoma-derived lines, were established in 1963. Since then, more than 1000 cell lines have been described, although not all of them in full detail. The major advantages of continuous cell lines is the unlimited supply and worldwide availablility of identical cell material, and the infinite viable storability in liquid nitrogen. LL cell lines are characterized generally by monoclonal origin and differentiation arrest, sustained proliferation in vitro under preservation of most cellular features, and specific genetic alterations. The most practical classification of LL cell lines assigns them to one of the physiologically occurring cell lineages, based on their immunophenotype, genotype and functional features. Truly malignant cell lines must be discerned from Epstein–Barr virus (EBV)-immortalized normal cells, using various distinguishing parameters. However, the picture is not quite so straightforward, as some types of LL cell lines are indeed EBV⁺, and some EBV⁺ normal cell lines carry also genetic aberrations and may mimic malignancy-associated features. Apart from EBV and human T-cell leukemia virus in some lines, the majority of wild-type LL cell lines are virus-negative. The efficiency of cell line establishment is rather low and the deliberate establishment of new LL cell lines remains by and large an unpredictable random process. Difficulties in establishing continuous cell lines may be caused by the inappropriate selection of nutrients and growth factors for these cells. Clearly, a generally suitable microenvironment for hematopoietic cells, either malignant or normal, cannot yet be created in vitro. The characterization and publication of new LL cell lines should provide important and informative core data, attesting to their scientific significance. Large percentages of LL cell lines are contaminated with mycoplasma (about 30%) or are cross-contaminated with other cell lines (about 15–20%). Solutions to these problems are sensitive detection, effective elimination and rigorous prevention of mycoplasma infection, and proper, regular authentication of cell lines. The underlying cause, however, appears to be negligent cell culture practice. The willingness of investigators to make their LL cell lines available to others is all too often limited. There is a need in the scientific community for clean and authenticated high-quality LL cell lines to which every scientist has access. These are offered by various institutionalized public cell line banks. It has been argued that LL cell lines are genetically unstable (both cytogenetically and molecular genetically). For instance, cell lines are supposed to acquire numerical and structural chromosomal alterations and various types of mutations (e.g. point mutations) in vitro. We present evidence that while nearly 100% of all LL cell lines indeed carry genetic alterations, these alterations appear to be stable rather than unstable. As an example of the practical utility of LL cell lines, the recent advances in studies of classical and molecular cytogenetics, which in large part were made possible by cell lines, are highlighted. A list of the most useful, robust and publicly available reference cell lines that may be used for a variety of experimental purposes is proposed. Clearly, by opening new avenues for investigation, studies of LL cell lines have provided seminal insights into the biology of hematopoietic neoplasia. Over a period of nearly four decades, these initially rather exotic cell cultures, known only to a few specialists, have become ubiquitous powerful research tools that are available to every investigator.
Effects of retinoic acid on a new human erythro-megakaryocytic cell line AP-217
1997, Leukemia Research
We have characterized a new human cell line AP-217, derived from the peripheral blood of a patient with chronic myeloid leukemia in blastic crisis.The analysis of cell surface antigens and ploidy showed that AP-217 was an erythro-megakaryocytic cell line.The effects of inducers of differentiation were studied and focused on retinoic acid (RA).Uninduced AP-217 cells produced a low level of hemoglobin (Hb) that showed a moderate but significant dose-dependent increase after 13 cis-RA induction (four times above the control at 10⁻⁵M).To outline this effect, AP-217 cells were cloned at limiting dilution.A subclone (clone 2) was isolated which expressed glycophorin A on 12% of cells, and showed a marked sensitivity to RA.After a 4 day induction with increasing concentrations of RA (1−10 × 10⁻⁶M) Hb production by clone 2 cells was enhanced 12 times over the control at the highest concentration (10⁻⁵ M). No effect of RA on the Hb production of K-562 and HEL was observed. This increased Hb production occurred simultaneously with a growth inhibition in clonogenic cultures (20% reduction) associated with a drastic reduction of the colony size.Moreover, we demonstrated the expression of mRNA for the β globin gene in clone 2 and AP-217-cells.This is the first report of a positive effect of RA on the erythroid differentiation of a human leukemic cell line.
Leukemia cell lines: In vitro models for the study of acute promyelocytic leukemia
1995, Leukemia Research
Acute promyelocytic leukemia (APL) serves as a paradigm in clinical and biological leukemia research. Firstly, APL represents a model for the new therapeutic approach of differentiation therapy, taking advantage of the ability of APL cells to respond to retinoic acid treatment by terminal differentiation. Secondly, the 15;17 chromosomal translocation specific for APL leads at the molecular genetic level to a chimeric gene fusing the PML and RARα genes and appears to be an instrumental, if not actually the causative event, in the neoplastic process. These unique characteristics of an otherwise rather rare disease have recently attracted intense research interest. As in other types of leukemia where continuous cell lines are powerful research tools, studies using APL-derived cell lines have contributed a large body of relevant data in efforts to unravel the pathobiology and leukemogenesis of APL. Three cell lines have been reported to be derived from patients with APL: HL-60, NB-4 and PL-21. Both HL-60 and PL-21 lack t(15;17) while NB-4 carries this cytogenetic hallmark pathognomonic for APL. Morphological and immunophenotypical examinations of the cell lines do not permit a clear assignment to any stage of myelomonocytic differentiation. Some additional data, such as expression of myeloperoxidase, monocyte-specific esterase and annexin VIII, together with the cytogenetic and molecular biological information, suggest that NB-4 is the only genuine promyelocytic leukemia cell line, whereas HL-60 may represent a discrete stage of differentiation between the late myeloblast and the promyelocyte; PL-21 has distinct features associated with monocytic cells. These cell lines provide unique in vitro model systems for studying the cellular and molecular events involved in the proliferation and differentiation of normal and leukemic myelomonocytic cells.

View all citing articles on Scopus

View full text

State of the artMyeloid cell lines: Tools for studying differentiation of normal and abnormal hematopoietic cells

Abstract

Blood

Blood

Blood

Blood

Blood

Leukemia Research

Immunology Letters

Cancer Genetics and Cytogenetics

Leukemia Research

Blood

Leukemia Research

Leukemia Research

Blood

Leukemia Research

Blood

Blood

Blood

Blood

Cell

Journal of the National Cancer Institute

Nature

Nature

Nature

Biochemistry Journal

Nature

International Journal of Cancer

Journal of Clinical Investigation

Constitutive uncoupling of pathways of gene expression that control growth and differentiation in myeloid leukemia. A model for the origin and progression of malignancy

Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture

Nature

Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity

Science

Establishment of a Ph1-positive human cell line (BV173)

Journal of the National Cancer Institute

Establishment of a Ph1-chromosome positive cell line from chronic myelogenous leukemia in blast crisis

International Journal of Cell Cloning

Two new human myeloid cell lines derived from acute promyelocytic leukemia and chronic myelocytic leukemia

Gann

EM-2 and EM-3: two new Ph1+ myeloid cell lines

Isolation of a new human myeloid leukeumia cell line, RDFD-2, and the preparation of clonal derivative lines with differing capacities to undergo induced maturation

Blood

HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression

Science

Kinetics of appearance of differentiation associated characteristics in ML-1, a line of human mycloblastic leukemia cells, after treatment with 12-0-tetradecanoylphorbol 13-acetate, dimethyl sulfoxide, 1-beta-D-arabinofuranoslycytosine

Cancer Research

Cell lines derived from a human monomyelocytic leukemia

British Journal of Haematology

Establishment, characterization and differentiation induction of a new human diploid myelomonocytic cell line (HL92) derived from a patient with acute myelomonocytic leukemia

Leukemia Research

Monocytoid leukemia cell line CTV-I: morphological, immunological and isoenzymatic characteristics

Tumour Biology

A new myeolomonoblastic cell line (M20): analysis of properties, differentiation, and comparison with other established lines of similar origin

Experimental Hematology

Establishment of a new myeloid leukemia cell line (TK-1), and isolation of a new myeloid leukemia cell line (TK-1), and isolation of cells having a translocation involving band 17q23

International Journal of Cancer

Establishment and characterization of a human histiocytic lymphoma cell line (U-937)

International Journal of Cancer

Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)

International Journal of Cancer

Establishment and characterization of four human monocytoid leukemia cell lines (JOSK-I, -S, -M and -K) with capabilities of monocyte-macrophage lineage differentiation and constitutive production of interleukin I

Cancer Research

Induction of monocyte/macrophage differentiation in a new diploid line of human hematopoetic cells (CM-S) by phorbol esters

Cancer Research

The generation of human monoctye/macrophage cell lines

Nature

Induction of megakaryocytic maturation of a human megakaryoblastic cell line

Experimental Hematology

Establishment and characterization of a megakaryoblastic cell line (CMK) from a Down's syndrome patient with acute megakaryoblastic leukemia

Experimental Hematology

State of the art
Myeloid cell lines: Tools for studying differentiation of normal and abnormal hematopoietic cells

Establishment of a Ph¹-positive human cell line (BV173)

Establishment of a Ph¹-chromosome positive cell line from chronic myelogenous leukemia in blast crisis

EM-2 and EM-3: two new Ph¹+ myeloid cell lines